BEAM THERAPEUTICS INC. - COMMON STOCK

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

26 3 2024 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

28 2 2024 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

27 2 2024 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

05 2 2024 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

08 1 2024 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 1 2024 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

14 12 2023 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

08 11 2023 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference

08 11 2023 06:30:00 提供 Nasdaq GlobeNewswire

Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

31 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT

25 10 2023 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline

19 10 2023 08:45:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation

07 9 2023 10:00:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL

05 9 2023 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming September Investor Conferences

31 8 2023 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results

08 8 2023 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming May Investor Conferences

17 5 2023 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference

11 5 2023 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results

10 5 2023 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day

27 3 2023 07:30:00 提供 Nasdaq GlobeNewswire